Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 2005

Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH

Silvia Peñuelas, Véronique Noé, Raúl Morales, Carlos J. Ciudad

Med Sci Monit 2005; 11(1): BR6-12 :: ID: 13864

Abstract

Background: Methotrexate (MTX) is an inhibitor of dihydrofolate reductase (DHFR), an enzyme involved in nucleotide synthesis, and is widely used in therapy, but its effi cacy is often compromised by the development of resistance in cancer cells. To identify potential targets as modulators in MTX chemotherapy, we determined gene expression profi les upon MTX treatment. Material/Methods: Expression profi les in human erythroleukemia K562 cells were determined after short treatment with MTX or once resistance to MTX was established. Screening was performed using the Atlas Human Cancer 1.2K arrays (BD-Clontech[sup]®[/sup]) containing 1176 cancer-related cDNAs. Specifi c software (Atlas Image 2.0.1 and Gene Spring 6.1) was used to analyze the expression level for each gene in each condition. Results were validated by quantitative RT-PCR, and the cytotoxicity of the
different treatments was assessed by the MTT assay. Results: Differentially expressed genes were selected considering a factor of 2 with respect to their expression in control cells. Eight genes were found to be overexpressed and 14 underexpressed both in MTX-treated and resistant cells. Among the overexpressed genes we chose 5’-onophosphate dehydrogenase (IMPDH2) for further validation. Changes in IMPDH2 mRNA levels were confi rmed and functional analyses were performed by inhibiting IMPDH with either benzamide riboside, mycophenolic acid, or tiazofurin. These inhibitors sensitized resistant K562 cells to MTX cytotoxicity. Conclusions: Expression of IMPDH2 is increased in K562 cells upon short treatment with MTX and once resistance to MTX is established. Benzamide riboside, mycophenolic acid, and tiazofurin could act as modulators of MTX chemotherapy in K562 cells.

Keywords: Antimetabolites, Antineoplastic - pharmacology, Cell Survival - drug effects, IMP Dehydrogenase - antagonists & inhibitors, IMP Dehydrogenase - metabolism, K562 Cells, Leukemia, Erythroblastic, Acute, Methotrexate - pharmacology, Oligonucleotide Array Sequence Analysis, Transcription, Genetic, Antimetabolites, Antineoplastic - pharmacology, Cell Survival - drug effects, IMP Dehydrogenase - metabolism, K562 Cells, Leukemia, Erythroblastic, Acute, Methotrexate - pharmacology, Oligonucleotide Array Sequence Analysis, Transcription, Genetic

Add Comment 0 Comments

Editorial

01 February 2025 : Editorial  

Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-Smokers

Dinah V. Parums

DOI: 10.12659/MSM.948255

Med Sci Monit 2025; 31:e948255

0:00

In Press

Clinical Research  

Predicting Cerebral Small Vessel Disease Burden Based on Thromboelastography in Patients with Acute Ischemi...

Med Sci Monit In Press; DOI: 10.12659/MSM.946303  

Clinical Research  

Long-Term Outcomes of Implanon in Managing Adenomyosis: A 3-Year Prospective Study

Med Sci Monit In Press; DOI: 10.12659/MSM.945972  

Laboratory Research  

Linear Dimensional Accuracy in Maxillomandibular Records: A Comparative Study of Scannable and Transparent ...

Med Sci Monit In Press; DOI: 10.12659/MSM.947265  

Clinical Research  

Efficacy of King's Combined Uterine Suture in Managing Placenta Accreta: A Retrospective Analysis

Med Sci Monit In Press; DOI: 10.12659/MSM.945826  

Most Viewed Current Articles

17 Jan 2024 : Review article   6,969,932

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   701,896

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   25,741

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   20,253

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750